Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuronetics ( (STIM) ) has provided an update.
On March 12, 2026, Neuronetics’ board appointed veteran medtech executive Daniel L. Reuvers as president and chief executive officer, with his tenure to begin around March 23, 2026 under an agreement that includes a $730,000 base salary, bonus eligibility, and a 1.5 million-unit restricted stock grant. The move follows a transformative 2025 in which revenue nearly doubled to $149.2 million, fueled by the Greenbrook TMS acquisition and strong clinic growth, and positions the company to build on improving cash generation, expanded insurance coverage, and new therapeutic collaborations as it targets further scale in the mental health treatment market.
Neuronetics reported fourth-quarter 2025 revenue of $41.8 million, up 86% year over year, with U.S. sales rising 88% and Greenbrook clinic revenue surging, while shipment of 49 NeuroStar systems and modest pro forma gains in treatment-session revenue underscored growing utilization. Management highlighted that the company exited 2025 with positive operating cash flow and a broader patient base—over 237,000 individuals treated in more than 8 million sessions—supporting its ambition to leverage its integrated platform and Reuvers’ commercialization experience to drive the next phase of growth in neurohealth therapies.
The most recent analyst rating on (STIM) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Neuronetics stock, see the STIM Stock Forecast page.
Spark’s Take on STIM Stock
According to Spark, TipRanks’ AI Analyst, STIM is a Neutral.
The score is held down primarily by weak financial durability (large losses, negative cash flow, and higher leverage) and bearish technicals (price below major moving averages with negative MACD). The latest earnings call provides some offset via strong reported revenue growth and improving cash burn with a near-term breakeven cash flow target, but margin pressure and reduced guidance keep the outlook cautious.
To see Spark’s full report on STIM stock, click here.
More about Neuronetics
Neuronetics, Inc., based in Malvern, Pa., is a vertically integrated, commercial-stage medical technology and healthcare company focused on mental health. Its core business centers on the NeuroStar Advanced Therapy System for treating depression and operating Greenbrook TMS clinics, with a strategy to deliver leading neurohealth therapies across clinic networks and broader patient populations.
The company also collaborates with partners such as Compass Pathways on emerging treatments like COMP360 psilocybin for treatment-resistant depression. Neuronetics serves both U.S. and international markets, and its growth is driven by device sales, clinic-based treatment sessions, and expanded reimbursement coverage for patients, including younger demographics under TRICARE West plans.
Average Trading Volume: 1,788,605
Technical Sentiment Signal: Sell
Current Market Cap: $93.14M
See more insights into STIM stock on TipRanks’ Stock Analysis page.